MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
ENDRA Life Sciences Cost of Revenue 2011-2026 | NDRA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 173 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 K | 173 K | 173 K |
Quarterly Cost of Revenue ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 118 K | 51.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 118 K | 51.4 K | 84.8 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
71 M | $ 20.54 | 2.55 % | $ 595 M |  USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 17.38 | 5.91 % | $ 525 M | USA |
 |
Guardant Health
GH
|
349 M | $ 118.01 | 2.64 % | $ 14.8 B | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 114.79 | 0.93 % | $ 34.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 116.57 | 1.29 % | $ 9.62 B |  Irlanda |
 |
Illumina
ILMN
|
1.51 B | $ 144.83 | 2.05 % | $ 23 B | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 3.71 | 55.23 % | $ 4.94 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 21.57 | 1.99 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 94.47 | -1.69 % | $ 6.38 B | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
53.9 M | $ 8.25 | 3.77 % | $ 736 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
413 M | $ 9.11 | 2.36 % | $ 1.17 B | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
158 M | $ 203.69 | -0.6 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 3.91 | 2.62 % | $ 362 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 27.15 | 1.53 % | $ 25.7 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 58.84 | 9.64 % | $ 3.52 B | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.16 | 7.88 % | $ 257 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.44 | 3.83 % | $ 5.6 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 255.75 | -0.65 % | $ 21.3 B | USA |
 |
Waters Corporation
WAT
|
363 M | $ 340.99 | -0.1 % | $ 20.3 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.63 | 3.42 % | $ 226 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Exagen
XGN
|
27.8 M | $ 4.27 | 11.49 % | $ 92.1 M | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.86 | 0.34 % | $ 1.92 B | USA |